Sponsors looking to develop drugs to treat dry eye should consider using both traditional environmental exposure and challenge-model trials, according to a December 2020 FDA draft guidance. Trials where the investigational drug is used as an add-on to a standardized treatment regimen are also acceptable, the guidance says.